Secular Trends in Neuroblastoma Mortality Before and After the Cessation of National Mass Screening in Japan

Kota Katanoda¹, Kunihiko Hayashi², Keiko Yamamoto², and Tomotaka Sobue¹

¹Cancer Information Services and Surveillance Division, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan
²Department of Basic Allied Medicine, School of Health Sciences, Gunma University, Maebashi, Japan

Received March 1, 2009; accepted April 26, 2009; released online August 1, 2009

ABSTRACT

Background: In 2003, the Japanese government halted the national mass screening program for neuroblastoma (NB), which had been running since the mid-1980s. It is not known whether the NB mortality rate subsequently increased or decreased.

Methods: Utilizing vital statistics data from 1980 through 2006, we analyzed the secular trends in NB mortality by using cancer of the adrenal gland as a surrogate. We examined the validity of this substitution by comparing the results with data from death certificates. Using a joinpoint regression model, we examined the trends in age-specific mortality rates by calendar year and cumulative mortality rates by birth year. The cumulative mortality rate was analyzed for age under 1 or 2 years for infants born after the cessation of the mass screening program.

Results: The number of deaths from cancer of the adrenal gland was closely correlated with the number of deaths from NB. Significant decreases in the mortality rate were observed from 1980 through 2006 by calendar year for those aged under 1 year, 1 to 4 years, and 5 to 9 years. The cumulative mortality rates by birth year also significantly decreased from the 1980 birth cohort. Although the cumulative mortality rates under the age of 2 appear to have increased after the 2003 birth cohort, the change was not statistically significant.

Conclusions: No significant increase in the NB mortality rate was detected after the cessation of the mass screening program in Japan. However, continuous monitoring is still needed to fully evaluate this health policy decision.

Key words: mass screening; mortality; neuroblastoma

INTRODUCTION

Studies conducted in Germany and in the province of Quebec, Canada showed that screening infants for neuroblastoma (NB) did not result in lower NB mortality.¹² Although a large number of epidemiological studies have been conducted in Japan, the findings regarding the effectiveness of NB screening have been inconsistent.³⁸ Clinical studies have reported that a considerable fraction of NB patients whose disease was detected by mass screening had favorable outcomes, which suggests the possibility of over-diagnosis.⁹¹⁴ In 2003, the Japanese government halted the national mass screening program—which had been in place since the mid-1980s for infants aged 6 months—because of the potential for over-diagnosis and the lack of evidence for its effectiveness in reducing NB mortality.¹⁵ Most local municipalities in Japan stopped the program during the following year. It is not known whether the NB mortality rate increased or decreased after this national change. Therefore, we analyzed secular trends in NB mortality in Japan before and after the cessation of the national mass screening program.

METHODS

As is the case in most countries, the Japanese government collects vital statistics data, in which the causes of death are classified according to the International Classification of Diseases (ICD). NB mortality cannot be directly identified in this classification because deaths attributable to NB are coded based on the organ affected, and are grouped together with deaths due to other cancers affecting the same organ.¹⁶ Two different methods have been adopted to address this issue. The first approach (hereafter referred to as method-1) is to extract the data on deaths due to cancer of the candidate sites, inspect the relevant individual death certificates, and identify NB...
deaths based on the description of the cause of death or the histological type. The second approach (hereafter referred to as method-2) is to use deaths from cancer of the adrenal gland as a surrogate index. Method-2 is less accurate than method-1 because NB can occur at sites other than the adrenal gland, and because other histological types of cancer can occur in this organ. Method-1 requires official permission for the use of unpublished vital statistics data, whereas method-2 uses only published vital statistics data, at least for the years after the ICD version 10 was applied.

The present study used method-1 to analyze data from the year 2006. We obtained individual mortality data from the vital statistics, with official permission, according to the following criteria: year of death = 2006; age at death = 0 to 14 years; cause of death (ICD) = malignant neoplasms of mediastinum (ICD-9 164.2, 164.3, 164.9; ICD-10 C38.1, C38.2, C38.8), connective and soft tissue (ICD-9 171.0, 171.2, 171.3, 171.4, 171.5, 171.6, 171.7, 171.8, 171.9), peripheral nerves and autonomic nervous system (ICD-10 C47.0, C47.1, C47.2, C47.3, C47.4, C47.5, C47.6, C47.8, C47.9), retroperitoneum and peritoneum (ICD-9 158.0, 158.8, 158.9; ICD-10 C48.0, C48.1, C48.2, C48.8), adrenal gland (ICD-9 194.0; ICD-10 C74.0, C74.1, C74.9), or other/ill-defined sites (ICD-9 195.0, 195.1, 195.2, 195.3, 195.4, 195.5, 195.8; ICD-10 C76.0, C76.1, C76.2, C76.3, C76.4, C76.5, C76.7, C76.8). Then, we inspected individual death certificates for the extracted data, and identified NB deaths based on the recorded causes of death or histological types. This process was performed by one of the authors (K. K.) and was confirmed by another author (K. Y., a pediatrician). For the data from 1980 through 2001, we obtained data on NB deaths from previous reports that had used a method identical to the present method-1 for extracting and identifying NB deaths. Thus, in the present study, data on the number of NB deaths based on method-1 were available for the years from 1980 through 2001, and for the year 2006. We could not apply method-1 to the time period from 2002 through 2005 because a previous application to use death certificates for research had been rejected, and the document storage period had expired by the time of our application.

For method-2, we calculated the age-specific number of deaths from adrenal gland cancer, based on officially obtained individual mortality data from the vital statistics. The criteria for data collection were as follows: year of death = 1980 to 2006; age at death = 0 to 14 years; cause of death (ICD) = malignant neoplasms of the adrenal gland (ICD-9 194.0; ICD-10 C74.0, C74.1, C74.9).

To validate method-2, we calculated the Pearson correlation coefficient between the number of NB deaths and the number of adrenal gland cancer deaths, using data from 1980 through 2001, and from 2006. We obtained population data from the published vital statistics and calculated the age-specific mortality rate by calendar year for cancer of the adrenal gland. For the age-specific mortality rate, age was stratified into the following 4 groups: 0 years, 1 to 4 years, 5 to 9 years, and 10 to 14 years. We also calculated the cumulative mortality rate by birth year, by summing the 1-year age-specific mortality rate according to each birth year. The number of deaths according to each age and each birth year was used as the numerator for the 1-year age-specific mortality rate. The denominator was the number of births (for age younger than 1 year) or the population for each age (for 1 year or older). The most recent birth year that we analyzed was 2005 for the cumulative mortality rate under 1 year of age, 2004 for 2 years of age, 2003 for 3 years of age, and 2002 for 4 years of age.

For the statistical analysis, we used a joinpoint regression model, implemented in the Joinpoint Regression Program (version 3.3.1) developed by the US National Cancer Institute. This method describes changes in data trends by connecting several different line segments on a log scale at joinpoints. The analysis starts with the minimum number of joinpoints (that is, 0, representing a straight line) and tests for the model fit with a maximum number of joinpoints. A Monte Carlo permutation method is used for tests of significance. In addition, the annual percent change (APC) for each line segment and the corresponding 95% confidence interval (CI) were estimated. In the statistical analysis, the number of deaths was assumed to follow a Poisson distribution. The maximum number of joinpoints was set at 3, the minimum number of observations from a joinpoint to either end of the data was set at 2 (including the end and joinpoint), and the minimum number of observations between 2 joinpoints was set at 4 (including the joinpoints).

RESULTS

Table 1 shows the secular trends in the age-specific number of deaths, according to the 2 methods. Although method-1 tended to yield slightly larger numbers than method-2, the secular trends were similar. The Pearson correlation coefficients between the annual numbers of deaths according to the 2 methods were close to 1 (1.00 for 0–14 years, 0.96 for <1 year, 0.98 for 1–4 years, 0.96 for 5–9 years, and 0.73 for 10–14 years; all 5 correlation coefficients were significantly different from 0 [number of data points = 23, P < 0.001]). In 2006, 45 deaths from cancer of the adrenal gland were observed, one of which was non-NB (malignant pheochromocytoma). In comparison, 45 NB deaths were identified by the inspection of death certificates from 2006, of which 1 case occurred at a site other than the adrenal gland (retroperitoneum).

Table 2 shows the results of the joinpoint analysis. Significant decreases in the age-specific mortality rate were observed from 1980 through 2006 by calendar year for those aged less than 1 year, 1 to 4 years, and 5 to 9 years. The cumulative mortality rates by birth year also significantly

J Epidemiol 2009;19(5):266-270
We examined the secular trends in the mortality rate for NB, using mortality for cancer of the adrenal gland as a surrogate index, and found no significant increase before or after the cessation of the Japanese national mass screening program. We confirmed the validity of this surrogate method by examining the correlation between the numbers of deaths from the 2 cancers. Nationwide mass screening had previously been performed for infants aged 6 months, and the participation level was high (ranging from 84% to 90% in the period from 1990 through 2001). Because the most recent year of death that we analyzed was 2006, any increase in the age-specific mortality rate associated with the cessation of mass screening in 2003 would have been expected to occur among children aged 1 to 4 years. However, we did not observe any significant increase or joinpoint in the mortality rate among this age group around this time. It is possible that the time elapsed since the cessation of mass screening was still too short to detect any increase in mortality for this age group, which decreased from the 1980 birth cohort. Figure 1 shows the trends in the age-specific mortality rate. The mortality rates for 1 to 4 years of age in 2004 and 2006 were high, but no significant increase or joinpoint was detected around this time. It is possible that the time elapsed since the cessation of mass screening was still too short to detect any increase in mortality for this age group, which decreased from the 1980 birth cohort. Figure 1 shows the trends in the age-specific mortality rate. The mortality rates for 1 to 4 years of age in 2004 and 2006 were high, but no significant increase or joinpoint was detected around this time. However, this change was not detected as a significant joinpoint.

### DISCUSSION

We examined the secular trends in the mortality rate for NB, using mortality for cancer of the adrenal gland as a surrogate index, and found no significant increase before or after the cessation of the Japanese national mass screening program. We confirmed the validity of this surrogate method by examining the correlation between the numbers of deaths from the 2 cancers. Nationwide mass screening had previously been performed for infants aged 6 months, and the participation level was high (ranging from 84% to 90% in the period from 1990 through 2001). Because the most recent year of death that we analyzed was 2006, any increase in the age-specific mortality rate associated with the cessation of mass screening in 2003 would have been expected to occur among children aged 1 to 4 years. However, we did not observe any significant increase or joinpoint in the mortality rate among this age group around this time. It is possible that the time elapsed since the cessation of mass screening was still too short to detect any increase in mortality for this age group, which did not occur.
included both screened and unscreened individuals, even at the end of our observation period.

The cumulative mortality rate according to birth year was a more direct index to examine the effect of the cessation of the mass screening program. It decreased significantly throughout the observed birth years, and the birth year 2003 was not detected as a significant joinpoint. However, these results should be interpreted with caution because the analyzed range of birth years and ages was limited after the cessation of the mass screening program. In consideration of the time from diagnosis to death, we should assume that any increase in the mortality rate for infants born after the cessation could occur later than the end of our observation period.

There are several Japanese municipalities that continued mass screening for NB after 2003. However, the number of such municipalities is very small, and our results did not change when we excluded the prefectures to which these municipalities belong (ie, Hokkaido, Kanagawa, Niigata, Shizuoka, Kyoto, Osaka, and Kumamoto).

We found a high correlation between the number of deaths from NB and the number of deaths from adrenal gland cancer, with the former slightly and consistently higher than the latter (Table 1). This tendency was in agreement with a previous report, in which approximately 90% of NB deaths were attributable to cancer of the adrenal gland, and almost all of the cancers that occurred at this site were NB. One death due

| Year | Mortality Rate (per 100,000 population) |
|------|----------------------------------------|
| 1980 | 1.2                                     |
| 1985 | 1.0                                     |
| 1990 | 0.8                                     |
| 1995 | 0.6                                     |
| 2000 | 0.4                                     |
| 2005 | 0.2                                     |

Figure 1. Annual trends in age-specific mortality rate for cancer of the adrenal gland, by calendar year

| Year | Cumulative Mortality Rate (per 100,000 population) |
|------|----------------------------------------------------|
| 1980 | 3.5                                                 |
| 1985 | 3.0                                                 |
| 1990 | 2.5                                                 |
| 1995 | 2.0                                                 |
| 2000 | 1.5                                                 |
| 2005 | 1.0                                                 |

Figure 2. Annual trends in cumulative mortality rate for cancer of the adrenal gland, by birth year. Note: The most recent analyzed birth year was 2005 for age <1 year, 2004 for age <2 years, 2003 for age <3 years, and 2002 for age <4 years

Katanoda K, et al. J Epidemiol 2009;19(5):266-270
to non-NB cancer in the adrenal gland was included among the data for 2006, but this was considered to be an unusual case.

The effect of the cessation of the mass screening program for NB should be verified by monitoring the trend in incidence. Studies have reported the trends in NB incidence and mortality before and after the start of a national mass screening program, based on data from a population-based cancer registry. Additional similar studies need to be conducted, and should include a sufficient observation period after the cessation of the program.

In conclusion, no significant increase in the NB mortality rate was detected after the cessation of the national mass screening program in Japan. However, continuous monitoring is still needed to evaluate further this health policy decision.

ACKNOWLEDGMENTS

This work was supported by Grants-in-aid for the Third-Term Comprehensive Ten-Year Strategy for Cancer Control from the Ministry of Health, Labour, and Welfare, Japan. The authors thank Dr. M. Nishi for his useful suggestions.

REFERENCES

1. Schilling FH, Spijk C, Berthold F, Erttmann R, Fehse N, Hero B, et al. Neuroblastoma screening at one year of age. N Engl J Med. 2002;346:1047–53.
2. Woods WG, Gao RN, Shuster JJ, Robison LL, Bernstein M, Weitzman S, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med. 2002;346:1041–6.
3. Ajiki W, Tsukuma H, Oshima A, Kawa K. Effects of mass screening for neuroblastoma on incidence, mortality, and survival rates in Osaka, Japan. Cancer Causes Control. 1998;9:631–6.
4. Hiyama E, Ichihara T, Sugimoto T, Fukuwata M, Hayashi Y, Sasaki F, et al. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study. Lancet. 2008;371:1173–80.
5. Honjo S, Doran HE, Stiller CA, Ajiki W, Tsukuma H, Oshima A, et al. Neuroblastoma trends in Osaka, Japan, and Great Britain 1970–1994, in relation to screening. Int J Cancer. 2003;103:538–43.
6. Nishi M, Miyake H, Takeda T, Hanai J, Kikuchi Y, Takasugi N. Mass screening for neuroblastoma and mortality in birth cohorts. Int J Cancer. 1997;71:552–5.
7. Suita S, Tajiri T, Akazawa K, Sera Y, Takamatsu H, Mizote H, et al. Mass screening for neuroblastoma at 6 months of age: difficult to justify. J Pediatr Surg. 1998;33:1674–8.
8. Yamamoto K, Ohta S, Ito E, Hayashi Y, Asami T, Mabuchi O, et al. Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan. J Clin Oncol. 2002;20:1209–14.
9. Matsumura M, Tsunoda A, Nishi T, Nishihira H, Sasaki Y. Spontaneous regression of neuroblastoma detected by mass screening. Lancet. 1991;338:447–8.
10. Nishihira H, Toyoda Y, Tanaka Y, Ijiri R, Aida N, Takeuchi M, et al. Natural course of neuroblastoma detected by mass screening: a 5-year prospective study at a single institution. J Clin Oncol. 2000;18:3012–7.
11. Okazaki T, Kohno S, Mimaya J, Hasegawa S, Unushihara N, Yoshida A, et al. Neuroblastoma detected by mass screening: the Tumor Board’s role in its treatment. Pediatr Surg Int. 2004;20:27–32.
12. Oue T, Inoue M, Yoneda A, Kubota A, Okuyama H, Kawahara H, et al. Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study. J Pediatr Surg. 2005;40:359–63.
13. Yamamoto K, Hanada R, Kikuchi A, Ichikawa M, Aihara T, Oguma E, et al. Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol. 1998;16:1265–9.
14. Yoneda A, Oue T, Imura K, Inoue M, Yagi K, Kawa K, et al. Observation of untreated patients with neuroblastoma detected by mass screening: a “wait and see” pilot study. Med Pediatr Oncol. 2001;36:160–2.
15. Tsubono Y, Hisamichi S. A halt to neuroblastoma screening in Japan. N Engl J Med. 2004;350:2010–1.
16. Hanawa Y, Sawada T, Tsunoda A. Decrease in childhood neuroblastoma death in Japan. Med Pediatr Oncol. 2000;18:472–5.
17. Nishi M, Takeda T, Hatae Y, Hanai J, Fujita K, Ichimiyi H, et al. Contribution of HPLC mass screening for neuroblastoma to a decrease in mortality. J Exp Clin Cancer Res. 2002;21:73–8.
18. Hayashi K, Fujita T, Katanoda K, Sobue T, Sato T, Nishi M, et al. Effectiveness of mass-screening program on neuroblastoma mortality in 1995–2000 birth cohort of Japan: Nationwide Neuroblastoma Mortality Study. Advances in Neuroblastoma Research 2004, Genoa, Italy.
19. Hayashi K. Epidemiologic evaluation of mass screening program for neuroblastoma. In: Kuroda Y, ed. Research on effective implementation and development of mass screening, Research on Measures for Intractable Diseases, Health and Labour Sciences Research Grants, 2004: 109–165.
20. Day N. Cumulative rate and cumulative risk. In: Muir C, Waterhouse J, Mack T, Powell J, Whelan S, editors. Cancer Incidence in Five Continents Volume V. Lyon: International Agency for Research on Cancer; 1987. p. 787–789.
21. Kim HH, Fay MP, Feuer EJ, Midhune DN. Permutation tests for jointpoint regression with applications to cancer rates. Stat Med. 2000;19:335–51.
22. Panel on Mass Screening Program for Neuroblastoma Ministry of Health, Labour and Welfare. A report on the mass screening program for neuroblastoma, 2003.